Biotransformation of organic nitrates and vascular smooth muscle cell function. 1994

B M Bennett, and B J McDonald, and R Nigam, and W C Simon
Department of Pharmacology and Toxicology, Queen's University, Kingston, Ontario, Canada.

The organic nitrates are interesting examples of drugs that undergo biotransformation at their site of action to generate the active form of the drug. Furthermore, tolerance to the vasodilator effects of organic nitrates is associated with impairment of this metabolic activation process. Despite considerable research effort, the intracellular processes and the chemical reaction pathways by which organic nitrates are converted to their active form are still unresolved. This review by Brian Bennett and colleagues summarizes the characteristics of organic-nitrate biotransformation in vascular smooth muscle, the difficulties encountered when assessing this biotransformation, and the evidence for the role of two identified vascular biotransformation systems (glutathione-S-transferases and the cytochrome P450 system) in the metabolic activation of organic nitrates.

UI MeSH Term Description Entries
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009566 Nitrates Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. Nitrate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

B M Bennett, and B J McDonald, and R Nigam, and W C Simon
October 1991, Biochemical and biophysical research communications,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
November 1989, Canadian journal of physiology and pharmacology,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
July 1971, Archives internationales de pharmacodynamie et de therapie,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
April 2021, British journal of pharmacology,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
November 1986, Japanese circulation journal,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
December 1998, Journal of hypertension,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
February 2010, Circulation research,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
October 2018, Laboratory investigation; a journal of technical methods and pathology,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
January 2020, Frontiers in pharmacology,
B M Bennett, and B J McDonald, and R Nigam, and W C Simon
December 2013, Free radical biology & medicine,
Copied contents to your clipboard!